Elevated levels of CA 19-9, a tumor marker, were found to be associated with decreased progression-free survival (PFS) in patients with colorectal peritoneal metastases (CRPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The study, which included 279 patients, showed that patients with elevated CA 19-9 had a much worse PFS rate compared to […]
Category: Cytoreductive Surgery & Peritoneum
Normal CEA Levels Predict Improved Survival in Colorectal Peritoneal Metastases
Normal CEA levels (≤ 2.5 ng/ml) after neoadjuvant chemotherapy (NACT) and cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) are associated with better survival in patients with colorectal peritoneal metastases (CRPM). A retrospective study on 253 CRPM patients showed that those with normal CEA levels after NACT had a median overall survival of 45.2 months, compared […]
Sodium thiosulfate effectively prevents cisplatin-induced nephrotoxicity in patients undergoing cytoreductive surgery with HIPEC
Sodium thiosulfate can effectively prevent cisplatin-induced nephrotoxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), eliminating the need for preoperative intravenous hyperhydration. A retrospective analysis of 220 patients showed that the use of sodium thiosulfate significantly reduced serum creatinine levels and preserved glomerular filtration rate compared to hyperhydration alone or in combination with […]
Improved Short-term Outcomes of Laparoscopic CRS-HIPEC compared to Open CRS-HIPEC in Peritoneal Metastasis
Laparoscopic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a safe and feasible procedure for selected patients with limited peritoneal disease. A retrospective analysis compared laparoscopic CRS-HIPEC to open CRS-HIPEC and found that laparoscopic procedures had lower estimated blood loss and overall morbidity rates. Grade III-IV complications, reintervention rates, and readmission rates were similar between […]
Prophylactic Hyperthermic Intraperitoneal Chemotherapy Improves Prognosis in CT4N0-1M0 Colorectal Cancer
A propensity score matching study analyzed 220 colorectal cancer patients undergoing treatment in China. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) was associated with improved 3-year disease-free survival (DFS) compared to no HIPEC (HR 0.43). However, this benefit was not observed in patients with CT4N2M0 cancer. Laparoscopic surgery followed by HIPEC did not increase the risk of […]
Limited peritoneal disease progression in gastric cancer patients: No survival benefit with gastrectomy + cytoreductive surgery and HIPEC
The study aimed to evaluate the impact of gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the outcomes of gastric cancer (GC) patients with limited peritoneal disease progression following neoadjuvant chemotherapy (NAC). Results showed that there was no survival benefit among advanced GC patients with peritoneal metastasis (PM) who underwent gastrectomy with […]
Improved Survival and Acceptable Complication Rates with Bidirectional Intraoperative Chemotherapy for Peritoneal Sarcomatosis
A retrospective cohort study analyzed 29 patients with peritoneal sarcomatosis who underwent cytoreductive surgery (CRS) with bidirectional intraoperative chemotherapy (BDIC) using intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC). The overall survival rates at 6, 12, 24, and 48 months after CRS/BDIC were 93.1%, 89.2%, 81.4%, and 73.3%, respectively. Disease recurrence rates were 15% at 6 […]
Defining Success in Colorectal Peritoneal Metastasis Surgery: International Consensus and Improved Survival
An international consensus has been reached on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The TOO parameters for CRS/HIPEC in this context include absence of certain complications, achievement of complete cytoreduction, and no contraindications for chemotherapy. A study cohort of 251 patients […]
Drug Response Heterogeneity Found in Patients Undergoing CRS/HIPEC for Nongynecologic Cancers
Among patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for nongynecologic cancers, intra- and interpatient drug response heterogeneity was observed. Researchers generated patient-derived tumor organoids (PDTOs) and conducted in vitro drug screens to assess drug response. PDTOs were successfully generated from 13 out of 23 patients, and drug screen results were obtained in as […]
Predictive Factors for Early Recurrence in Metastatic Colorectal Cancer Treated with Combined Liver Resection and HIPEC
The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2 status) had a higher risk of early recurrence, while retroperitoneal […]